Our Services
Medical Information
Helpful Resources
Published on: 10/27/2026
Imodium Multi-Symptom Relief chewable tablets combine two active ingredients, loperamide hydrochloride 2 mg (which slows diarrhea) and simethicone 125 mg (which eases gas and bloating), and age limits apply. The label directs that children under 6 should not take this product, and that a doctor should be consulted before giving it to children ages 6 to 11, while ages 12 and up can follow adult dosing. Dehydration risk, bloody or black stools, fever, and recent antibiotic use are important warning signs that change whether this medicine is appropriate at all. There are several other factors to weigh, including dosing caps, serious heart rhythm risks from too much loperamide, and when diarrhea needs urgent care, so see below for the complete details before giving it to a child.
If you are unsure whether your child's diarrhea, gas, or stomach pain calls for an anti-diarrheal, fluids alone, or a same-day visit, a free, instant, online symptom check can help you sort it out in just a few minutes. It asks about age, symptom duration, and red flags that parents often overlook, then outlines likely causes and sensible next steps so you are not guessing in the medicine aisle. It takes less time than reading a drug label and can help you decide whether to treat at home or call a clinician now.
Last reviewed for medical accuracy: 10/27/2026
Imodium Multi-Symptom Relief Chewables are generally labeled for adults and children age 12 and older. They are not an appropriate routine treatment for younger children unless a doctor specifically recommends them. The medicine contains two active ingredients: loperamide hydrochloride and simethicone.
Although Imodium can reduce diarrhea quickly, diarrhea in children can sometimes be caused by infection, food poisoning, medication, or another medical problem. Children can also become dehydrated faster than adults. For these reasons, age limits and warning signs matter.
This guidance is based on the FDA-approved product labeling, FDA safety information, and pediatric diarrhea guidance from reputable medical organizations. Always check the Drug Facts label on the specific package you have, because formulations and directions may change.
Each Imodium Multi-Symptom Chewable typically contains:
These ingredients address symptoms, not necessarily the cause of diarrhea. Simethicone does not treat an infection, and loperamide does not eliminate viruses or bacteria.
For Imodium Multi-Symptom Relief Chewables, the usual labeled age limit is 12 years and older. Children younger than 12 should not be given this combination product unless a healthcare professional tells you to use it.
Do not assume that an adult formulation is safe for a younger child simply because the child is large for their age. Dosing depends on the medicine, the child’s age and weight, the cause of diarrhea, and the child’s overall health.
Important age-related points include:
The product label takes priority. If your child is younger than the labeled age, contact the child’s doctor or a pharmacist rather than trying to adjust the tablet or dose yourself.
For people age 12 and older, the U.S. product directions commonly recommend an initial dose followed by a smaller dose after later loose stools. The exact directions and maximum daily amount depend on the product, so read the package carefully.
Do not:
Taking too much loperamide can cause serious heart problems, including abnormal heart rhythms, fainting, and cardiac arrest. This is uncommon when the medicine is used correctly, but the risk rises substantially with excessive doses.
Do not use this medicine to treat diarrhea when a child has symptoms that could indicate a more serious illness. Speak to a doctor promptly if diarrhea is accompanied by:
Loperamide can slow the intestines and may make some bacterial or inflammatory diarrheal illnesses worse. It should generally be avoided when there is bloody diarrhea, high fever, or suspected dysentery unless a doctor has advised otherwise.
Stop the medicine and seek medical advice if the child develops constipation, increasing abdominal swelling, severe pain, or an allergic reaction.
For most children with uncomplicated diarrhea, replacing lost fluid and salts is more important than immediately stopping every loose stool. Offer frequent small amounts of an oral rehydration solution made for children. These products contain the right balance of water, sugar, and electrolytes.
If the child is vomiting, try a spoonful or small sip every few minutes rather than a large drink all at once. Breastfed babies should usually continue breastfeeding. Normal age-appropriate foods can often be continued if the child wants to eat.
Avoid relying on soda, undiluted juice, sports drinks, or very sugary beverages. They may contain too much sugar and not enough of the electrolytes a child loses through diarrhea.
Possible signs of dehydration include:
A baby, young child, or teenager with these symptoms should receive prompt medical assessment.
There is no single over-the-counter diarrhea medicine that is right for every child. Younger children are usually managed with fluids, monitoring, and treatment of the underlying cause. A doctor may recommend a specific product in selected situations, but parents should not substitute an adult combination medicine.
Before giving any diarrhea remedy, consider the child’s:
A pharmacist can help check for duplicate ingredients and interactions. If you are unsure whether symptoms need medical attention, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It should support—not replace—professional medical care.
Imodium Multi-Symptom Chewables contain loperamide and simethicone and are generally intended for adults and children age 12 and older. They should not be used in younger children without advice from a doctor or pharmacist. Even for an older child, do not use them when there is blood in the stool, high fever, severe pain, abdominal swelling, significant vomiting, or signs of dehydration.
Focus first on oral rehydration and careful observation. Speak to a doctor about anything that could be life-threatening or serious, including severe dehydration, confusion, fainting, persistent vomiting, bloody diarrhea, or a child who is difficult to wake.
(References)
* Advice for travelers. Med Lett Drugs Ther. 2019 Oct 7;61(1582):153-160. PMID: 31599872.
* Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A, NALA Investigators. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. PMID: 32678716; PMCID: PMC7499616.
* Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 Jan 19;77(2):205-223. doi: 10.1016/j.jacc.2020.11.002. PMID: 33446314.
* Levine M, Lovecchio F. New Designer Drugs. Emerg Med Clin North Am. 2021 Aug;39(3):677-687. doi: 10.1016/j.emc.2021.04.013. Epub 2021 Jun 9. PMID: 34215409.
* Vearrier D, Grundmann O. Clinical Pharmacology, Toxicity, and Abuse Potential of Opioids. J Clin Pharmacol. 2021 Aug;61 Suppl 2:S70-S88. doi: 10.1002/jcph.1923. PMID: 34396552.
* Daoub M, Cawley P, Sahu J. Loperamide-induced ventricular tachycardia storm. Br J Cardiol. 2021;28(4):46. doi: 10.5837/bjc.2021.046. Epub 2021 Oct 13. PMID: 35747063; PMCID: PMC9063705.
* Ryoo SB. Low anterior resection syndrome. Ann Gastroenterol Surg. 2023 Sep;7(5):719-724. doi: 10.1002/ags3.12695. Epub 2023 May 23. PMID: 37663958; PMCID: PMC10472409.
* Bhandari B, Siddique S, Tahir S, Link MG. Loperamide-Induced Torsades de Pointes. Cureus. 2024 Jul;16(7):e64427. doi: 10.7759/cureus.64427. Epub 2024 Jul 12. PMID: 39130993; PMCID: PMC11317118.
* Remes-Troche JM, Coss-Adame E, Schmulson M, García-Zermeño KR, Amieva-Balmori M, Carmona-Sánchez R, Gómez-Escudero O, Gómez-Castaños PC, Icaza-Chávez ME, López-Colombo A, Morel-Cerda EC, Valdovinos-Díaz MÁ, Valdovinos-García LR, Villar-Chávez AS. Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024. Rev Gastroenterol Mex (Engl Ed). 2025 Jan-Mar;90(1):77-110. doi: 10.1016/j.rgmxen.2024.10.009. Epub 2025 Apr 29. PMID: 40307155.
* Terrat J, Joly O, Marcot D. Abus à visée récréative des médicaments délivrés sans ordonnance en Suisse. Rev Med Suisse. 2026 Mar 11;22(953):496-500. doi: 10.53738/REVMED.2026.22.953.47104. PMID: 41811742.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.